Adult Immunization

CD388, an investigational nonvaccine antiviral, demonstrated efficacy up to 76% against influenza in a cohort of more than 5000 healthy, unvaccinated adults.

The vaccine showed superior relative vaccine efficacy that was 26.6% higher than a licensed standard-dose influenza vaccine, Moderna reported.

FDA panel endorses continued use of monovalent JN.1 strain for COVID-19 vaccines, aligning with global health recommendations amid evolving variants.

Moderna voluntarily withdrew the BLA after consultation with the FDA and will resubmit once it has additional phase 3 efficacy data for its investigational flu shot.

Your daily dose of the clinical news you may have missed.

Nuvaxovid (NVX-CoV2373) is indicated for those aged ≥65 years and aged 12 to 64 years with at least one condition that puts them at high risk for severe infection.

Cases of whooping cough in the US more than doubled in 2024, and 2 infants have died from the infection. Here is background on the infection and vaccine.

Misinformation about measles and the MMR vaccine has reached the majority of US adults and parents; most believe the vaccine is safe but many are still unconvinced.

Novavax’s COVID-19 vaccine was linked to fewer and less severe side effects vs mRNA in a University of Utah study of health care workers.

Respiratory syncytial virus was deadly and untreatable across the lifespan until 2023 when the first vaccines were approved in the US. Follow the timeline, here.